Takeda to buy Millennium for $8.8 billion

Share this article:
Takeda Pharmaceutical of Japan has announced plans to purchase US biotech firm Millennium Pharmaceuticals in a deal valued at nearly $9 billion.

The deal is the largest transaction involving a Japanese company so far this year and brings the Osaka-based Takeda a new therapeutic area -- cancer treatments.

Millennium's leading product is Velcade, a blood cancer treatment expected to generate revenues of as much as $345 million this year, according to analysts. Millennium also has seven compounds in clinical trials. Those compounds are designed to treat cancer, Crohn's disease and multiple sclerosis.

The Millenium deal is the latest of a handful pulled off by Takeda in recent months.

In February, Takeda brokered a deal to purchase Amgen's Japan unit and gain marketing rights to 13 Amgen drugs for Japan and Asia. In March, Takeda bought out partner Abbott Laboratories in its TAP Pharmaceuticals joint venture.

Takeda is Japan's largest drugmaker in terms of revenue but is staring at looming patent expiration on its biggest-selling products – the proton pump inhibitor Prevacid which expires in 2009, and diabetes treatment Actos, which will see expiry in 2011.

Takeda has arranged to purchase Cambridge, MA-based Millennium for $25 a share, or a total of $8.8 billion. The price represents a sweet 53% premium to Wednesday's $16.35 closing price for Millennium's stock, the Wall Street Journal reported. The deal is conditional upon a majority of shareholders accepting the terms.
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...